Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?

Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?Making the first move in <i>EGFR</i>-driven or <i>ALK</i>-driven NSCLC: first-generation or next-generation TKI?, Published online: 14 August 2018; doi:10.1038/s41571-018-0081-4The clinical management of patients with non-small-cell lung carcinoma has greatly evolved owing to the development of tyrosine-kinase inhibitors (TKIs) targeted against the driver mutations of this disease. The authors of this Review describe the existing evidence on the sequential administration of TKIs and the use of next-generation TKIs upfront.
Source: Nature Clinical Practice Oncology - Category: Cancer & Oncology Authors: Source Type: research